Carasent AB (publ) (STO:CARA)
Sweden · Delayed Price · Currency is SEK | Market Cap | 1.81B -5.4% |
| Revenue (ttm) | 389.84M +18.5% |
| Net Income | 39.53M |
| EPS | 0.57 |
| Shares Out | 67.39M |
| PE Ratio | 46.98 |
| Forward PE | 29.48 |
| Dividend | 1.89 (7.02%) |
| Ex-Dividend Date | n/a |
| Volume | 45,424 |
| Open | 26.50 |
| Previous Close | 26.45 |
| Day's Range | 26.45 - 27.05 |
| 52-Week Range | 21.70 - 29.45 |
| Beta | 0.27 |
| Analysts | n/a |
| Price Target | 34.92 (+29.81%) |
| Earnings Date | Oct 15, 2026 |
About Carasent AB
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It also provides Medrave, Vårdrummet, Ad Voca, and HPI Plustoo services, as well as an ecosystem of platform services, including solutions for patient communication and business intelligence. The company was founded in 1997 and is headquartered in Gothenburg, Sweden. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
The average 12-month stock price target for CARA is kr 34.92, which is an increase of 29.81% from the latest price.
News
Carasent AB Earnings Call Transcript: Q3 2026
Q3 revenue reached SEK 108m, up 12% organically, while EBITDA margin rose to 20%. Nordic momentum remained strong, but German churn and the slower Webcur launch weighed on progress; Medsum adoption and new customer wins supported growth.
Carasent AB Quarterly report: Q3 2026
Carasent AB has published its Q3 2026 quarterly earnings report on October 15, 2026.
Carasent AB Slides: Q3 2026
Carasent AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 15, 2026.
Carasent AB Earnings Call Transcript: Q2 2026
Q2 saw robust recurring revenue growth, improved profitability, and strong cash flow, bolstered by the InfoSolutions acquisition and cost savings. AI and product innovation continue to drive customer wins, while regulatory and market dynamics shape adoption pace and pricing.
Carasent AB Slides: Q2 2026
Carasent AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 10, 2026.
Carasent AB Quarterly report: Q2 2026
Carasent AB has published its Q2 2026 quarterly earnings report on July 10, 2026.
Carasent AB Earnings Call Transcript: Q1 2026
ARR grew 16% year-over-year with strong profitability and 19% growth in the Nordics, while German revenues declined due to legacy churn. AI-driven product enhancements and Medsum adoption are key growth drivers, with share buybacks and targeted acquisitions planned.
Carasent AB Quarterly report: Q1 2026
Carasent AB has published its Q1 2026 quarterly earnings report on April 14, 2026.
Carasent AB Slides: Q1 2026
Carasent AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 14, 2026.
Carasent AB Earnings Call Transcript: Q4 2025
Q4 saw 15% organic ARR growth, a 16% EBITDA margin, and strong profitability, driven by major client migrations and high consulting revenues. AI investments continue, with Medsom now using OpenAI, and the sales pipeline remains robust, especially in the Nordics.
Carasent AB Annual report: Q4 2025
Carasent AB has published its Q4 2025 annual report on February 12, 2026.
Carasent AB Quarterly report: Q4 2025
Carasent AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
Carasent AB Slides: Q4 2025
Carasent AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.